ANIX
Anixa Biosciences IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$86.84M
P/E Ratio
—
EPS
$-0.32
Beta
0.58
52W High
$5.46
52W Low
$2.38
50-Day MA
$2.86
200-Day MA
$3.40
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company is headquartered in San Jose, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-13.10M |
| Operating Margin | 0.00% |
| Return on Equity | -68.10% |
| Return on Assets | -40.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.45 |
| Price-to-Book | 5.67 |
| Price-to-Sales (TTM) | 377.78 |
| EV/Revenue | 274.8 |
| EV/EBITDA | -8.76 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $33.53M |
| Float | $31.72M |
| % Insiders | 5.38% |
| % Institutions | 17.06% |
Analyst Ratings
Consensus ($10.75 target)
1
Strong Buy3
BuyData last updated: 4/7/2026